Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pTTL
- Development stage
- Phase 2
- Lead developer
- Neogap Therapeutics
- Modality
- Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
pTTL is an autologous cell therapy product for adoptive cancer immunotherapy, primarily developed for advanced colorectal cancer. It consists mainly of in vitro expanded T cells that are enriched for neoantigen-specific clones derived from the patient's own lymph nodes. The product also contains small proportions of NK and B cells, with a variable CD4/CD8 T cell ratio and a significant proportion of memory T cells expressing markers indicative of functionality. pTTL is administered as a single-dose monotherapy following chemotherapy-based preconditioning (cyclophosphamide and fludarabine). Its mechanism involves the expansion and infusion of patient-specific tumor-reactive lymphocytes to enhance anti-tumor immune responses[5][7].
- Other names
- personalized tumor-trained lymphocytes
02
Targets
Neoantigen-specific T-cell receptor
Beyond the preview
Go deeper on pTTL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pTTL.